Flux Power Holdings Inc vs Viatris Inc — how do they compare? Flux Power Holdings Inc trades at $0.48 (market cap $9.97M), while Viatris Inc trades at $17.48 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 2009× Flux Power Holdings Inc's market cap, and Viatris Inc pays a 2.75% dividend while Flux Power Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Flux Power Holdings Inc for 20 Days and Viatris Inc for 57 Days on average.
| FLUX | VTRS | |
|---|---|---|
Market Cap | $9.97M | $20.03B |
Volume | 817,320 | 14,109,977 |
Sector | Industrials | Health |
52-Week High | $6.66 | $18.27 |
52-Week Low | $0.41 | $9.74 |
Typical Hold Time | 20 Days | 57 Days |
Enterprise Value | $18.18M | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
FLUX trades at $0.49, down 0.55% today, amid ongoing acquisition interest from Solidion Technology. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal declining revenue from $66M in 2025 to $42M in 2026 and persistent net losses. Despite unanimous analyst buy ratings, recent earnings misses and negative profitability metrics (-17.68% net margin) highlight operational challenges.
The outlook remains speculative with acquisition potential offering upside, but fundamental weakness and cash flow concerns pose significant risks. Investors face a binary outcome between takeover premium and continued operational losses in the competitive energy storage sector.
Viatris (VTRS) trades at $17.49, down 0.29% with a bullish technical signal supported by moving averages and oversold RSI levels. The company shows consistent earnings beats with Q2 2026 EPS of $0.69 exceeding expectations, while maintaining strong operational cash flow of $2.32B in 2025. Recent developments include FDA approval for WAKIX in Japan and continued recognition as a top employer.
Despite negative net margins, Viatris demonstrates improving cash flow trends and strategic portfolio optimization. The stock offers 27% upside to consensus price target of $22.17, though investors face risks from debt levels and competitive pressures in the generic drug market. Deleveraging progress and pipeline advancements support potential re-rating.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →